Showing Latest Articles
Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases
Modern Rheumatology, 08/26/2011
Dalkilic E et al. – Findings of several reports suggest that rituximab, a chimeric monoclonal anti–CD20 antibody causing B–lymphocyte depletion, might represent a treatment option for people with granulomatosis with polyangiitis (GPA) (former Wegener’s granulomatosis).
- This study presents the results of rituximab treatment in two patients with treatment–refractory GPA.
- First patient received rituximab for a granulomatous posterior orbital mass lesion, and eye symptoms were resolved after three courses of treatment.
- The second patient had eye and paranasal sinus involvement and benefited from two courses of rituximab treatment, with significant clinical improvement.
- Rituximab may represent an effective novel treatment for remission induction in GPA.